GlassScriptPhysician profile
Olivia Rose Ryder
NPI 1518496645
$17,410.29
in general payments reported to CMS, 2019-2025
67 companies · $4,680 in 2025
The $4,680 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $108 · 2021: $446 · 2022: $3,466 · 2023: $3,029 · 2024: $4,602 · 2025: $4,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $22.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,288.08 |
| Education | $22.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,938.58 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,532.88 | 2019-2025 | |
| Ucb, INC. | $1,282.56 | 2022-2025 | Rystiggo, Briviact, Nayzilam |
| Celgene Corporation | $1,162.30 | 2021-2025 | Zeposia |
| Biogen, INC. | $759.84 | 2021-2025 | Vumerity, Tysabri |
| Genzyme Corporation | $678.38 | 2019-2025 | |
| Genentech USA, INC. | $651.05 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Alexion Pharmaceuticals, INC. | $590.49 | 2019-2025 | Ultomiris |
| Pfizer INC. | $529.31 | 2022-2025 | |
| Lundbeck LLC | $462.50 | 2021-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $449.37 | 2021-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $437.55 | 2021-2023 | Ponvory |
| Emd Serono, INC. | $420.87 | 2022-2025 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $400.44 | 2022-2025 | Hyqvia, Gammagard |
| Lilly USA, LLC | $332.32 | 2022-2025 | Kisunla, Emgality, Reyvow |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $320.53 | 2021-2025 | Crexont, Rytary, Ongentys |
| Amgen INC. | $309.73 | 2021-2025 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $303.11 | 2019-2025 | Austedo Xr |
| Horizon Therapeutics Plc | $286.64 | 2021-2023 | Uplizna |
| Acadia Pharmaceuticals INC | $284.59 | 2022-2025 | Nuplazid |
| Eisai INC. | $258.80 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $242.96 | 2023-2025 | Purified Cortrophin Gel |
| Argenx US, INC. | $242.82 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tg Therapeutics, INC. | $240.99 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $236.10 | 2025 | Ponvory |
| Alnylam Pharmaceuticals INC. | $225.20 | 2022-2025 | Onpattro |
| Jazz Pharmaceuticals INC. | $192.51 | 2022-2025 | |
| Neurelis, INC. | $189.89 | 2021-2025 | Valtoco |
| Kyowa Kirin, INC. | $175.08 | 2022-2025 | Nourianz |
| Sk Life Science, INC. | $174.72 | 2020-2025 | Xcopri |
| Impel Pharmaceuticals INC. | $167.43 | 2022-2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $146.94 | 2023-2024 | Aptiom |
| Corium, LLC | $143.40 | 2022-2023 | Adlarity |
| Harmony Biosciences LLC | $141.43 | 2021-2025 | |
| Alkermes, INC. | $125.00 | 2019 | |
| Mdd US Operations, LLC | $122.60 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $107.36 | 2023-2025 | Rexulti, Nuedexta |
| Catalyst Pharmaceuticals, INC. | $88.82 | 2022-2025 | Fycompa |
| Aucta Pharmaceuticals, INC. | $77.88 | 2024-2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $59.94 | 2025 | Tascenso Odt, Bafiertam |
| Tanabe Pharma America, INC. | $53.86 | 2024-2025 | Radicava |
| Avanir Pharmaceuticals, INC. | $52.83 | 2022 | |
| Cala Health, INC. | $52.16 | 2022-2023 | Cala Trio |
| Sunovion Pharmaceuticals INC. | $51.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $51.11 | 2021 | |
| Supernus Pharmaceuticals, INC. | $49.36 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $46.31 | 2025 | Keveyis |
| Zogenix INC. | $45.75 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $44.37 | 2025 | Lumryz |
| Axsome Therapeutics, INC. | $43.53 | 2025 | Symbravo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.51 | 2024 | Rexulti |
| Scilex Pharmaceuticals INC. | $40.15 | 2023 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $37.83 | 2022 | |
| Acorda Therapeutics, INC | $36.16 | 2022 | |
| Azurity Pharmaceuticals, INC. | $36.16 | 2023-2024 | Horizant, Horizant |
| Csl Behring | $27.66 | 2022-2023 | Hizentra |
| Octapharma USA, INC. | $24.58 | 2025 | Panzyga |
| Spr Therapeutics, INC | $24.25 | 2025 | Sprint Pns System |
| Janssen Biotech, INC. | $24.04 | 2025 | |
| Medtronic, INC. | $21.98 | 2022 | |
| Hospira, INC. | $21.97 | 2024 | |
| Collegium Pharmaceutical, INC. | $19.86 | 2022 | |
| Alk-Abello, INC | $16.48 | 2024 | Odactra, Grastek, Ragwitek |
| Ge Healthcare | $15.07 | 2023 | |
| Allergan, INC. | $14.78 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.84 | 2021 | |
| Mallinckrodt Hospital Products INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Ryder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.